209 related articles for article (PubMed ID: 1703827)
1. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
[TBL] [Abstract][Full Text] [Related]
3. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
4. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
Milbradt H; Flik J; Stangel W; Heigel R
Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
[TBL] [Abstract][Full Text] [Related]
6. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation.
Kelsey SM; Newland AC
Bone Marrow Transplant; 1989 Sep; 4(5):543-6. PubMed ID: 2551435
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
10. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
11. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection after bone marrow transplantation in children.
Castagnola E; Cappelli B; Erba D; Rabagliati A; Lanino E; Dini G
Hum Immunol; 2004 May; 65(5):416-22. PubMed ID: 15172440
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infection in the bone marrow transplant recipient.
Zaia JA; Forman SJ
Infect Dis Clin North Am; 1995 Dec; 9(4):879-900. PubMed ID: 8747771
[TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
Funada H; Harada M; Yoshida T; Hattori K
Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
[TBL] [Abstract][Full Text] [Related]
16. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
19. Prevention of CMV infection after BMT in high-risk patients using CMV hyperimmune globulin.
Einsele H; Vallbracht A; Schmidt H; Friese M; Schüch K; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
Cancer Detect Prev; 1988; 12(1-6):637-41. PubMed ID: 2846173
[TBL] [Abstract][Full Text] [Related]
20. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]